Technical Analysis for CALC - CalciMedica, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Narrow Range Bar | Range Contraction | -1.19% | |
| Wide Bands | Range Expansion | -1.19% | |
| Down 3 Days in a Row | Weakness | -1.19% | |
| Oversold Stochastic | Weakness | -1.19% | |
| Wide Bands | Range Expansion | -2.06% | |
| Oversold Stochastic | Weakness | -2.06% |
| Alert | Time |
|---|---|
| Down 2 % | 1 day ago |
| Fell Below Previous Day's Low | 1 day ago |
| Down 1% | 1 day ago |
| Up 2% | 1 day ago |
| Up 1% | 1 day ago |
Get a Trading Assistant
- Earnings date: 11/07/2024
CalciMedica, Inc. Description
CalciMedica is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. CalciMedica’s proprietary technology targets the inhibition of calcium release-activated calcium (CRAC) channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are currently no approved therapies. CalciMedica’s lead product candidate Auxora, a proprietary, intravenous-formulated CRAC channel inhibitor, has demonstrated positive and consistent clinical results in four completed efficacy clinical trials. Auxora is in development for acute pancreatitis and asparaginase-associated pancreatitis. CalciMedica was founded by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research, and is headquartered in La Jolla, CA.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Medication Inflammatory Diseases Abdominal Pain Pancreatitis Acute Pancreatitis Asparaginase
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.38 |
| 52 Week Low | 2.68 |
| Average Volume | 55,172 |
| 200-Day Moving Average | 4.53 |
| 50-Day Moving Average | 4.05 |
| 20-Day Moving Average | 3.74 |
| 10-Day Moving Average | 3.46 |
| Average True Range | 0.28 |
| RSI (14) | 37.50 |
| ADX | 12.36 |
| +DI | 21.78 |
| -DI | 23.14 |
| Chandelier Exit (Long, 3 ATRs) | 4.68 |
| Chandelier Exit (Short, 3 ATRs) | 4.11 |
| Upper Bollinger Bands | 4.47 |
| Lower Bollinger Band | 3.01 |
| Percent B (%b) | 0.22 |
| BandWidth | 38.86 |
| MACD Line | -0.21 |
| MACD Signal Line | -0.18 |
| MACD Histogram | -0.0279 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.59 | ||||
| Resistance 3 (R3) | 3.59 | 3.52 | 3.54 | ||
| Resistance 2 (R2) | 3.52 | 3.45 | 3.51 | 3.53 | |
| Resistance 1 (R1) | 3.42 | 3.41 | 3.39 | 3.42 | 3.51 |
| Pivot Point | 3.35 | 3.35 | 3.33 | 3.34 | 3.35 |
| Support 1 (S1) | 3.25 | 3.28 | 3.22 | 3.25 | 3.15 |
| Support 2 (S2) | 3.18 | 3.24 | 3.17 | 3.13 | |
| Support 3 (S3) | 3.08 | 3.18 | 3.12 | ||
| Support 4 (S4) | 3.08 |
